Threading an Antigen Through the Eye of Patentability to Sew Up Profits: Biogen Inc v Medeva plc

Research output: Contribution to journalArticle


Criticism of HL ruling that patent for hepatitis B virus antigen was invalid because claim was too broad, insufficiently inventive and unsupported by disclosure.
Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalInternational Journal of Biosciences and the Law
Issue number3
Publication statusPublished - 1 Jan 1997
Externally publishedYes


Cite this